The article examines the therapeutic use of Psilocybin, a component of some species of magic mushrooms, which is a 5HT2A serotonin receptor agonist and a hallucinogenic agent.Carhart-Harris, R. L.Bolstridge, M.Rucke, J.BJPsych International...
New research suggests psilocybin has similar side effects to traditional antidepressants. Commonly referred to as "magic mushrooms," psilocybin is a promising alternative treatment for people with medication-resistant depression and anxiety. Previous studies have suggested that the psychedelic fungi can have...
The dosage and intensity of magic mushrooms depends not only on the species, but where it was grown and how it has been handled. For example, there are several different strains ofP. cubensis; ThaiP. cubensismushrooms are considered to be stronger and can result in a more intense high, w...
The U.S. government still classifies the chemical as a controlled substance, with no accepted medical use. Several cities have already decriminalized magic mushrooms and Oregon is the first state to approve medical use. Philip Corlett, an associate psychiatry professor at Yale University, said many...
Hallucinogens likemagic mushroomsare known for their mind-altering affects that leave users feeling like they've had profound, life-changing experiences. Now scientists are experimenting with the psychedelic drug to see what else psilocybin—the active ingredient in mushrooms—can do. ...
NEW YORK --Thepsychedelic drugin “magic mushrooms” can quickly and effectively help treatanxietyand depression in cancer patients, an effect that may last for months, two small studies show. It worked for Dinah Bazer, who endured a terrifying hallucination that rid her of the fear that her ...
Psilocybin -- "magic mushrooms" -- failed to improve symptoms of depression over a selective serotonin reuptake inhibitor (SSRI) in a 59-patient phase II trial, though the study's leaders are not ready to give up on the hallucinogen. ...
The US Federal Drug Administration has given the go-ahead to a London-based startup to begin drug trials using psilocybin, the main active psychedelic compound in magic mushrooms, to treat depression. The startup, Compass Pathways, funded by Silicon Valley billionaire Peter Thiel, is on the for...
The US Food and Drug Administration (FDA) has given psilocybin – the psychoactive ingredient in ‘magic mushrooms’ – breakthrough therapy designation, due to the potential it holds as a treatment for depression. The designation is granted to therapies for which preliminary evidence suggests pote...
Mushrooms do not have physiologic symptoms of addiction. Though, long-term abusers of mushrooms may experience depression, insomnia, or “flashbacks”. A flashback is the experience of a mushroom trip days, months or years after using the drug. These unexpected “psychedelic trips” can be caused...